![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/KILITCH.png)
Share the post "Kilitch Drugs (India) ‘s Q3 2024-25 Latest News: Profit Grows by 222.99% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 76.65 % in the past year, substantial increase in net sales/revenue by 18.31 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -41.64 %, Marginal decrease of -66.6% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Kilitch Drugs (India) Limited. Notable increase of 222.33 % in net profit Year to Year, Kilitch Drugs (India) Limited’s profitability dropped by -34.8 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS increased by 100.54 % Year to Year. EPS decreased by -30.78 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 31.795 Cr | Rs. 47.475 Cr | Rs. 56.166 Cr | + 18.31 % | + 76.65 % |
| Expenses | Rs. 29.51 Cr | Rs. 41.38 Cr | Rs. 47.43 Cr | + 14.62 % | + 60.73 % |
| Operating Profit | Rs. 2.29 Cr | Rs. 6.1 Cr | Rs. 8.74 Cr | + 43.28 % | + 281.66 % |
| OPM % | 7.2 % | 12.85 % | 15.56 % | + 2.71 % | + 8.36 % |
| Other Income | Rs. 2.956 Cr | Rs. 5.164 Cr | Rs. 1.725 Cr | -66.6 % | -41.64 % |
| Interest | Rs. 1.6 Cr | Rs. 0.31 Cr | Rs. 1.4 Cr | + 351.61 % | -12.5 % |
| Depreciation | Rs. 0.82 Cr | Rs. 0.61 Cr | Rs. 0.81 Cr | + 32.79 % | -1.22 % |
| Profit before tax | Rs. 2.83 Cr | Rs. 10.34 Cr | Rs. 8.26 Cr | -20.12 % | + 191.87 % |
| Tax % | 38.29 % | 16.77 % | 31.95 % | + 15.18 % | -6.34 % |
| Net Profit | Rs. 1.74 Cr | Rs. 8.61 Cr | Rs. 5.62 Cr | -34.73 % | + 222.99 % |
| EPS in Rs | Rs. 1.85 | Rs. 5.36 | Rs. 3.71 | -30.78 % | + 100.54 % |
Today, we’re looking at Kilitch Drugs (India) Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 76.65 %. However, it did see a marginal increase of 18.31 % from the previous quarter. Expenses ticked up slightly by 14.62 % quarter-on-quarter, aligning with the annual rise of 60.73 %. Operating profit, while up 281.66 % compared to last year, faced a quarter-on-quarter increase of 43.28 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 8.36 %, but an expansion of 2.71 % sequentially. Other income fell by -66.6 % compared to the last quarter, despite an annual decline of -41.64 %. Interest expenses surged remarkably by 351.61 % from the previous quarter, yet the year-over-year decrease remains at a moderate -12.5 %. Depreciation costs climbed by 32.79 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -1.22 %. Profit before tax grew annually by 191.87 % but saw a reduction from the preceding quarter by -20.12 %.
Tax expenses as a percentage of profits decreased slightly by -6.34 % compared to last year, with a more notable quarter-on-quarter increase of 15.18 %. Net profit rose by 222.99 % year-on-year but witnessed a -34.73 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 100.54 % but a quarterly fall of -30.78 %. In summary, Kilitch Drugs (India) Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 31.795 Cr | Rs. 47.475 Cr | Rs. 56.166 Cr | + 18.31 % | + 76.65 % |
| Expenses | Rs. 29.51 Cr | Rs. 41.38 Cr | Rs. 47.43 Cr | + 14.62 % | + 60.73 % |
| Operating Profit | Rs. 2.29 Cr | Rs. 6.1 Cr | Rs. 8.74 Cr | + 43.28 % | + 281.66 % |
| Net Profit | Rs. 1.74 Cr | Rs. 8.61 Cr | Rs. 5.62 Cr | -34.73 % | + 222.99 % |
| EPS in Rs | Rs. 1.85 | Rs. 5.36 | Rs. 3.71 | -30.78 % | + 100.54 % |
In reviewing Kilitch Drugs (India) Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 76.65 % year-on-year growth, however, there was a minor increase of 18.31 % from the previous quarter. Expenses rose by 60.73 % compared to the previous year, with a 14.62 % increase quarter-on-quarter. Operating Profit surged by 281.66 % annually, and saw a 43.28 % increase from the last quarter.
Net Profit showed yearly increase of 222.99 %, and experienced a -34.73 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 100.54 % annually, however dipped by -30.78 % compared to the last quarter. In essence, while Kilitch Drugs (India) Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GOACARBON.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/HCC.png)